REPUBLIQUE
ET CANTON
DE GENEVE

The business results of the OM PHARMA group in 2008 have reached an all time high, with a consolidated turnover of 131.7 million CHF (unaudited results), an 18 % increase with respect to 2007. This represents worldwide sales of OM PHARMA products of 240 million CHF.

Among the record sellers, Broncho-Vaxom®, the immunostimulating bacterial extract aimed at preventing respiratory tract infections, reached 105 million CHF in local sales, a 21% increase with close to 120 million capsules being bought worldwide. The revenues of the other bacterial extract Uro-Vaxom®, prescribed for the prevention of urinary tract infections, totalled 17.3 million CHF.

About the OM PHARMA groupOM PHARMA is a Swiss-based independent biotech-pharma company founded in 1937 in Geneva, with subsidiaries in Portugal and Peru. Its global workforce totals 500 including 200 in Switzerland.The headquarters are located in Meyrin/Geneva, Switzerland, where it opened in 2005 a state of the art biotech centre for the production of its leader immunotherapeutic products, Broncho-Vaxom® and Uro-Vaxom®, recommended for the prevention of respiratory respectively urinary tract infections. Different lead products are manufactured in its other new plant in Alfragide/Lisbon, Portugal, such as the vascular medications Doxium® and Dicynone®.R&D activities are focussed on immunology, allergy and vaccines.OM PHARMA is certified ISO 9001:2000 (quality) and ISO 14001:2004 (environment).More information on www.ompharma.com